Skip to content
OpenCapital
Get started

Jazz Pharmaceuticals JAZZ Rebates and other sales deductions

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept jazz:AccruedRebatesAndOtherSalesDeductionsCurrent.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's rebates and other sales deductions.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's rebates and other sales deductions?
Jazz Pharmaceuticals (JAZZ) reported rebates and other sales deductions of $484.3M in Q1 2026.
How has Jazz Pharmaceuticals's rebates and other sales deductions changed year-over-year?
Jazz Pharmaceuticals's rebates and other sales deductions increased by 9.4% year-over-year, from $442.77M to $484.3M.
What is the long-term trend for Jazz Pharmaceuticals's rebates and other sales deductions?
Over 3 years (2022 to 2025), Jazz Pharmaceuticals's rebates and other sales deductions has grown at a 13.7% compound annual growth rate (CAGR), from $313.18M to $459.8M.